Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minimal Residual Disease (MRD)-Guided Adjuvant Therapy in Stage I Non-Small Cell Lung Cancer: A Prospective, Multicenter, Randomized Controlled Study

NCT06709274 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.

NCT NCT06709274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06709274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minimal Residual Disease (MRD)-Guided Adjuvant Therapy in Stage I Non-Small Cell Lung Cancer: A Prospective, Multicenter, Randomized Controlled Study
Lead sponsor
Guangdong Association of Clinical Trials
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 30, 2024
Completion date
January 31, 2032
Enrollment
342 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer